Zenotech Laboratories Reports ₹3.15 Cr Net Loss in Q4 on Tax Write-offs

Zenotech Laboratories announced a net loss of ₹3.15 Crores for the quarter ended March 31, 2026. This quarterly loss contributed to a full-year net loss of ₹1.07 Crores, a significant shift from the previous year's profitability.

Financial Performance Details

The company's financial results for the year ended March 31, 2026, revealed a stark contrast to FY25, when it reported a net profit. Full-year revenue saw a modest increase of 2.98% to ₹45.92 Crores. However, quarterly revenue declined sharply by 17.01% year-on-year to ₹10.48 Crores, signalling potential challenges towards the end of the fiscal year.

The reported loss was significantly influenced by one-time financial events. These included substantial tax reversals, amounting to ₹187.47 Lakhs in MAT credit and ₹157.82 Lakhs in deferred tax assets. Exceptional costs of ₹24.48 Lakhs related to past service costs for gratuity and leave encashment also impacted the bottom line. Despite these financial pressures, the statutory auditors issued an unmodified, or clean, audit opinion, indicating no major accounting concerns.

Historical Context and Risks

This year's net loss marks a departure from prior years. Historically, Zenotech Laboratories has faced challenges in sales growth, averaging only 10.6% over the past five years. Its return on equity stood at a low 9.52% over the last three years, and debtor days have risen from 40.3 to 63.2 days, suggesting potential working capital management issues. These ongoing factors, combined with the recent revenue dip and the impact of non-recurring items, present key risks to the company's financial health.

Industry and Future Outlook

Zenotech Laboratories operates in the competitive Indian pharmaceutical sector, alongside companies like Indoco Remedies, Laurus Labs, Aurobindo Pharma, Alkem Laboratories, Sun Pharma, Divi's Laboratories, and Torrent Pharmaceuticals. Investors will be closely watching for management commentary on the drivers of the Q4 revenue decline and strategies to improve sales growth and profitability. Future performance will hinge on effective cost management and the company's ability to navigate its ongoing financial and operational challenges.

Key Figures:

• Standalone Total Revenue for FY26: ₹45.92 Crores
• Standalone Net Loss for Q4 FY26: ₹3.15 Crores